Federated Investors Inc. PA grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 424,349 shares of the healthcare product maker’s stock after purchasing an additional 4,102 shares during the period. Federated Investors Inc. PA’s holdings in Abbott Laboratories were worth $25,428,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Point72 Asset Management L.P. purchased a new stake in shares of Abbott Laboratories during the third quarter worth approximately $47,713,000. Folger Hill Asset Management LP purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $1,398,000. Teachers Insurance & Annuity Association of America increased its stake in shares of Abbott Laboratories by 7.4% during the fourth quarter. Teachers Insurance & Annuity Association of America now owns 240,902 shares of the healthcare product maker’s stock worth $13,748,000 after buying an additional 16,502 shares during the period. Zeke Capital Advisors LLC increased its stake in shares of Abbott Laboratories by 3.2% during the fourth quarter. Zeke Capital Advisors LLC now owns 70,476 shares of the healthcare product maker’s stock worth $4,022,000 after buying an additional 2,198 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Abbott Laboratories by 7.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 708,263 shares of the healthcare product maker’s stock worth $40,421,000 after buying an additional 46,818 shares during the period. Institutional investors own 72.09% of the company’s stock.
A number of analysts recently weighed in on the stock. Citigroup cut their target price on shares of Abbott Laboratories from $66.00 to $65.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 24th. ValuEngine upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. BTIG Research restated a “hold” rating on shares of Abbott Laboratories in a research note on Sunday, April 22nd. Argus upped their target price on shares of Abbott Laboratories from $66.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 30th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research note on Friday, April 20th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $68.35.
In related news, Director Daniel J. Starks purchased 40,037 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were bought at an average cost of $60.67 per share, for a total transaction of $2,429,044.79. Following the completion of the purchase, the director now directly owns 6,943,348 shares of the company’s stock, valued at approximately $421,252,923.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Sharon J. Bracken sold 2,150 shares of the stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $58.56, for a total transaction of $125,904.00. Following the completion of the transaction, the senior vice president now owns 43,990 shares in the company, valued at $2,576,054.40. The disclosure for this sale can be found here. Insiders sold 32,516 shares of company stock worth $1,976,970 over the last quarter. 0.74% of the stock is currently owned by insiders.
Shares of Abbott Laboratories stock opened at $62.37 on Friday. The company has a market capitalization of $108.42 billion, a price-to-earnings ratio of 24.95, a P/E/G ratio of 1.78 and a beta of 1.50. Abbott Laboratories has a 52 week low of $43.83 and a 52 week high of $64.60. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.24 and a current ratio of 1.66.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 18th. The healthcare product maker reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.01. The company had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 earnings per share. analysts anticipate that Abbott Laboratories will post 2.86 EPS for the current fiscal year.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.